Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has been given an average rating of “Moderate Buy” by the thirteen brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $25.4615.

A number of analysts have recently commented on KURA shares. Mizuho cut their price target on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 24th. Wedbush decreased their price objective on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Citizens Jmp restated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday, June 15th. Finally, Wells Fargo & Company set a $24.00 price target on Kura Oncology in a research report on Thursday, June 4th.

Kura Oncology Trading Up 3.0%

Shares of NASDAQ:KURA opened at $11.10 on Friday. The firm has a market cap of $985.35 million, a price-to-earnings ratio of -3.31 and a beta of 0.35. Kura Oncology has a 12 month low of $5.45 and a 12 month high of $12.49. The company’s fifty day simple moving average is $9.69 and its 200 day simple moving average is $9.20. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. The firm had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. As a group, research analysts forecast that Kura Oncology will post -3.45 EPS for the current fiscal year.

Insider Activity

In related news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider directly owned 182,345 shares in the company, valued at approximately $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently added to or reduced their stakes in the business. IFP Advisors Inc increased its position in Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after acquiring an additional 1,284 shares during the period. EverSource Wealth Advisors LLC raised its position in Kura Oncology by 392.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after purchasing an additional 3,072 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after buying an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Kura Oncology by 127.2% during the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.